drugApproval News & Analysis
3 articles
Market Mood
Gilead Sciences (GILD) Stock Rating Reiterated After HIV Drug Approval
Cantor Fitzgerald has reiterated its rating on Gilead Sciences (GILD) following the approval of a new HIV drug. The approval is significant as it supports Gilead's position in the HIV treatment market. Market analysts are closely watching the impact of this approval on Gilead's stock performance and overall revenue growth. Investors should consider this reaffirmed rating when evaluating their positions in GILD, given the potential for increased sales.
Read More
Travere (TVTX) FDA Approves FILSPARI for Rare Kidney Disease
Travere Therapeutics Inc. (NASDAQ:TVTX) received FDA approval on April 13 for FILSPARI (sparsentan), making it the first medication approved to treat focal segmental glomerulosclerosis (FSGS). The approval is backed by data from the Phase 3 DUPLEX Study, which showed a 48% reduction in proteinuria for treated patients after 108 weeks, compared to 27% for the comparator drug. This approval expands TVTX's market potential to over 100,000 patients in the U.S. with FSGS, alongside its existing indication for IgA nephropathy. This positions Travere to grow in the rare kidney disease sector, which could positively impact its market valuation.
Read More
Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Eli Lilly (LLY) received US approval for its weight-loss drug, Foundayo. This approval introduces competition in the oral obesity drug market, particularly against Novo Nordisk. The specifics of the approval, including safety and efficacy data, have not been disclosed in this article. The entry of Foundayo may influence market dynamics as both companies vie for market share in the oral obesity treatment space.
Read More